AI Article Synopsis

  • - The study assessed the safety and effectiveness of combining camrelizumab and apatinib in patients with advanced esophageal squamous cell carcinoma (ESCC) who previously received immune checkpoint inhibitors (ICIs).
  • - Out of 49 patients treated, the confirmed objective response rate was 10.2%, with a disease control rate of 69.4% and median progression-free survival of 4.6 months.
  • - The results indicated that the response rate was modest and did not show significant improvement, though the treatment had a manageable safety profile with no treatment-related deaths reported.

Article Abstract

Background: With the increasing use of immune checkpoint inhibitors (ICIs) in advanced esophageal squamous cell carcinoma (ESCC), there remains an unmet need for options to address disease progression after prior ICIs. This single-arm phase II study evaluated the efficacy and safety of re-challenge with camrelizumab plus apatinib in patients with advanced ESCC who were previously treated with ICIs.

Methods: This study enrolled patients aged 18-75 years with unresectable locally advanced, locally recurrent, or distant metastatic ESCC who received prior ICIs. Patients received intravenous camrelizumab 200 mg every 2 weeks and oral apatinib 250 mg daily until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was the investigator-assessed confirmed objective response rate (ORR).

Results: Between September 1, 2021 and March 29, 2023, 49 eligible patients were enrolled and received treatment. Among the 49 patients, the confirmed ORR was 10.2 % (95 % CI 3.4-22.2), the disease control rate (DCR) was 69.4 % (54.6-81.7), the median progression-free survival (PFS) was 4.6 months (95 % CI 3.8-6.5) and overall survival (OS) was 7.5 months (5.5-13.6). Grade ≥ 3 treatment-related adverse events occurred in 17 patients (34.7 %). No treatment-related deaths occurred.

Conclusions: This study showed that the confirmed ORR was modest and did not reach clinically meaningful improvement for patients with ESCC who were previously treated with ICIs, with a manageable safety profile.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2024.114328DOI Listing

Publication Analysis

Top Keywords

efficacy safety
8
camrelizumab apatinib
8
patients
8
apatinib patients
8
patients advanced
8
advanced esophageal
8
esophageal squamous
8
squamous cell
8
cell carcinoma
8
immune checkpoint
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!